<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - METHYLPHENIDATE HYDROCHLORIDE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>METHYLPHENIDATE HYDROCHLORIDE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#treatmentCessation" data-toggle="tab">Treatment cessation</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Attention deficit hyperactivity disorder (initiated under specialist supervision)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using immediate-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 5 mg 2&#8211;3 times a day, dose is increased if necessary at weekly intervals according to response, increased if necessary up to 100 mg daily in 2&#8211;3 divided doses, if effect wears off in evening (with rebound hyperactivity) a dose at bedtime may be appropriate (establish need with trial bedtime dose). Treatment may be started using a modified-release preparation.</li>
              <li class="dose child"><strong>For children 6&#8211;17 years</strong><br/>
                Initially 5 mg 1&#8211;2 times a day, increased in steps of 5&#8211;10 mg daily if required, at weekly intervals, increased if necessary up to 60 mg daily in 2&#8211;3 divided doses, increased if necessary up to 2.1 mg/kg daily in 2&#8211;3 divided doses, the licensed maximum dose is 60 mg daily in 2&#8211;3 doses, higher dose under the direction of a specialist, discontinue if no response after 1 month, if effect wears off in evening (with rebound hyperactivity) a dose at bedtime may be appropriate (establish need with trial bedtime dose). Treatment may be started using a modified-release preparation; maximum 90 mg per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Narcolepsy</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using immediate-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10&#8211;60 mg daily in divided doses; usual dose 20&#8211;30 mg daily in divided doses, dose to be taken before meals.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Limited experience&#8212;avoid unless potential benefit outweighs risk.</p>
            </section>
      </section>



      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Anorexia nervosa</li>
            <li>arrhythmias</li>
            <li>cardiomyopathy,</li>
            <li>cardiovascular disease</li>
            <li>cerebrovascular disorders</li>
            <li>heart failure</li>
            <li>hyperthyroidism</li>
            <li>phaeochromocytoma</li>
            <li>psychosis</li>
            <li>severe depression</li>
            <li>severe hypertension</li>
            <li>structural cardiac abnormalities</li>
            <li>suicidal ideation</li>
            <li>uncontrolled bipolar disorder</li>
            <li>vasculitis</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, aggression, alopecia, anorexia, arrhythmias, arthralgia, asthenia, changes in blood pressure, cough, depression, diarrhoea, dizziness, drowsiness, dry mouth, dyspepsia, fever, growth restriction, headache, insomnia, irritability, movement disorders, nasopharyngitis, nausea, nervousness, palpitation, pruritus, rash, reduced weight gain, tachycardia, tics, vomiting,
              </p>
              <p>
                <strong>uncommon:</strong> Abnormal dreams, confusion, constipation, dyspnoea, epistaxis, haematuria, muscle cramps, suicidal ideation, urinary frequency,
              </p>
              <p>
                <strong>rare:</strong> Angina, sweating, visual disturbances;,
              </p>
              <p>
                <strong>veryRare:</strong> Angle-closure glaucoma, blood disorders, cerebral arteritis, dependence, erythema multiforme, exfoliative dermatitis, hepatic dysfunction, leucopenia, myocardial infarction, neuroleptic malignant syndrome, psychosis, seizures, thrombocytopenia, tolerance, Tourette syndrome,
              </p>
              <p>
                <strong>notKnown:</strong> Bradycardia, convulsions, supraventricular tachycardia,
              </p>
        
        
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE</h3>
              <p outputclass="specificity">In children</p> <p outputclass="title">Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) (March 2006)</p> <p> Methylphenidate is recommended, within its licensed indications, as an option for the management of ADHD in children and adolescents.</p><xref format="html" href="http://www.nice.org.uk/TA98">www.nice.org.uk/TA98</xref>
                <a href="http://www.nice.org.uk/TA98" target="_blank">www.nice.org.uk/TA98</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Agitation
          </li>
          <li>
            alcohol dependence
          </li>
          <li>
            anxiety
          </li>
          <li>
            drug dependence
          </li>
          <li>
            epilepsy (discontinue if increased seizure frequency)
          </li>
          <li>
            family history of Tourette syndrome
          </li>
          <li>
            susceptibility to angle-closure glaucoma
          </li>
          <li>
            tics
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor for psychiatric disorders.</p>
            </section>
            <section class="patientParameters">
              <p>Pulse, blood pressure, psychiatric symptoms, appetite, weight and height should be recorded at initiation of therapy, following each dose adjustment, and at least every 6 months thereafter.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Not licensed for use in children under 6 years; doses over 60&#8239;mg daily not licensed; doses of <i>Concerta XL</i> over 54&#8239;mg daily not licensed.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">In adults</h3>
              <p>Not licensed for use in narcolepsy.</p><p>Not licensed for use in adults for attention deficit hyperactivity disorder.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Different versions of modified-release preparations may not have the same clinical effect. To avoid confusion between these different formulations of methylphenidate, prescribers should specify the brand to be dispensed.</p>
            </section>
      </section>

      <section class="tab-pane" id="treatmentCessation">
        <h2>Advice regarding ceasing treatment</h2>

            <section class="treatmentCessation">
              <p>Avoid abrupt withdrawal.</p>
            </section>
      </section>








      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of METHYLPHENIDATE HYDROCHLORIDE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            modified-release tablet,
            oral suspension,
            oral solution,

            <div id="PHP77721"><a href="../medicinalForm/PHP77721.html" data-target="#PHP77721" data-action="load">Tablet</a></div>
            <div id="PHP77726"><a href="../medicinalForm/PHP77726.html" data-target="#PHP77726" data-action="load">Modified-release tablet</a></div>
            <div id="PHP77740"><a href="../medicinalForm/PHP77740.html" data-target="#PHP77740" data-action="load">Modified-release capsule</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
